Search

Your search keyword '"Alegre, Adrián"' showing total 340 results

Search Constraints

Start Over You searched for: Author "Alegre, Adrián" Remove constraint Author: "Alegre, Adrián"
340 results on '"Alegre, Adrián"'

Search Results

1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

2. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

3. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

4. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

5. LibreOffice. Nociones básicas para gestión de la información (calc - writer - impress)

6. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

7. Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting.

8. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

9. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

10. Gestión de comunidades virtuales en Bibliotecas. Un propuesta teórico-práctica. Ponencia inaugural del Encuentro de Bibliotecarios de Toledo 2014

11. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

13. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

14. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma. Results of the Compassionate Use or the Expanded Access Program in Spain

16. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

17. El Crossumer: la evolución del consumidor mediada por las tecnologías sociales y la hiperconectividad móvil

18. Transplant results in adults with Fanconi anaemia

20. P-090: Immune biomarkers of survival and infectionrelated mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)

21. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

22. Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

23. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

24. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

26. Gestió documental i codi obert, dues peces d'un mateix trencaclosques

27. Los dominios semánticos marcan la nueva era de Internet

28. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

30. Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005

31. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

32. ¿Tienen sentido las palabras clave de los artículos científicos?

33. Bibliotecas privadas de la Edad Media

34. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

35. WhatsApp (poco a poco) en la biblioteca

36. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

41. Therapeutic Efficacy of a Plasma Rich in Growth Factors Gel Combined with Fractional Ablative Laser in the Management of Post-acne Scars.

42. Reseña de Los Sexenios de Investigación

43. MORA VILLAREJO, L. (ed.) Catálogo de fondo antiguo con tipografía árabe: una colección singular en la Biblioteca Islámica Félix M.ª Pareja

44. MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis

45. Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies

46. MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies

47. Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis

48. Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

49. Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

50. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

Catalog

Books, media, physical & digital resources